Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 22Gastrointestinal 4Head & Neck 3Dermatologic 3Breast 3Thoracic 2Lymphoid 2Gynecologic 2Genitourinary 2Endocrine 1CNS 1

Conditions

Lymphoma 11Lymphoma, Non-Hodgkin 10Multiple Myeloma 9Leukemia, Lymphocytic, Chronic, B-Cell 9Hodgkin Disease 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Neoplasms 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Hematologic Neoplasms 5Burkitt Lymphoma 5Neuroblastoma 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4Lymphoma, B-Cell 4Leukemia, Myeloid, Acute 4Breast Neoplasms 4Neoplasm Metastasis 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Melanoma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Waldenstrom Macroglobulinemia 2Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2

Interventions

Magnetic Resonance Spectroscopy 6Cyclophosphamide 6X-Rays 5Phantoms, Imaging 5Filgrastim 5pembrolizumab 4Specimen Handling 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Gemcitabine 4Biopsy 4tazemetostat 3Surveys and Questionnaires 3Psychiatric Rehabilitation 3Etoposide 3Drug Therapy 3Carboplatin 3Busulfan 3Bevacizumab 3ulixertinib 2tipifarnib 2spartalizumab 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2ganitumab 2ensartinib 2aflibercept 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sarcoma × Ipilimumab × Lymphoid × Clear all
NCT03058289 2025-02-27

IT-01

Intensity Therapeutics, Inc.

Phase 1/2 Completed
111 enrolled 21 charts
BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT01445379 2019-12-17

Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
33 enrolled
CNSGenitourinaryLymphoidSarcoma

Lymphoma, Wilms Tumor, Neuroblastoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡